Total Payments
$69,506
2024 Payments
$1,716
Companies
8
Transactions
54
Medicare Patients
2,230
Medicare Billing
$1.3M
Payment Breakdown by Category
Other$50,625 (72.8%)
Research$14,739 (21.2%)
Consulting$1,440 (2.1%)
Food & Beverage$1,411 (2.0%)
Education$1,160 (1.7%)
Travel$131.10 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,625 | 26 | 72.8% |
| Unspecified | $14,739 | 10 | 21.2% |
| Consulting Fee | $1,440 | 1 | 2.1% |
| Food and Beverage | $1,411 | 14 | 2.0% |
| Education | $1,160 | 2 | 1.7% |
| Travel and Lodging | $131.10 | 1 | 0.2% |
Payments by Type
General
$54,767
44 transactions
Research
$14,739
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ferring Pharmaceuticals Inc. | $37,908 | 28 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $14,917 | 9 | $0 (2021) |
| Eli Lilly and Company | $14,739 | 10 | $0 (2021) |
| CONMED Corporation | $1,440 | 1 | $0 (2019) |
| Boston Scientific Corporation | $332.51 | 3 | $0 (2024) |
| Ardelyx, Inc. | $66.35 | 1 | $0 (2024) |
| Ethicon Inc. | $65.90 | 1 | $0 (2017) |
| PFIZER INC. | $37.27 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,716 | 3 | Ferring Pharmaceuticals Inc. ($1,526) |
| 2023 | $36,465 | 28 | Ferring Pharmaceuticals Inc. ($36,382) |
| 2022 | $125.88 | 1 | Boston Scientific Corporation ($125.88) |
| 2021 | $3,842 | 4 | Takeda Pharmaceuticals U.S.A., Inc. ($3,220) |
| 2020 | $7,171 | 7 | Takeda Pharmaceuticals U.S.A., Inc. ($5,911) |
| 2019 | $10,673 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($5,786) |
| 2018 | $4,072 | 3 | Eli Lilly and Company ($4,035) |
| 2017 | $5,442 | 2 | Eli Lilly and Company ($5,376) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,526.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/05/2024 | Boston Scientific Corporation | EXALT Model D (Device) | Food and Beverage | In-kind items and services | $123.63 | General |
| Category: EXALT Model D_ENDO | ||||||
| 03/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $66.35 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/06/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,433.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/06/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $93.01 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,526.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 08/30/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Education | In-kind items and services | $580.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/18/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,433.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 07/06/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,722.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/20/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,526.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/20/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,526.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/19/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $136.89 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/19/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $113.39 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/04/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $278.02 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/01/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $843.42 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/01/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $672.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 06/01/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $278.02 | General |
| Category: GASTROENTEROLOGY | ||||||
| 04/11/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,433.50 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/21/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $9,919.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/09/2023 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $83.00 | General |
| Category: General - Biliary Devices_ENDO | ||||||
| 02/21/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $122.57 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/14/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Education | In-kind items and services | $580.00 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/04/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $567.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/04/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $383.34 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/03/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $383.34 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2 MULTICENTER RANDOMIZED PARALLEL-ARM PLACEBO-CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH ACTIVE CROHNS DISEASE (SERENITY) | Eli Lilly and Company | $10,504 | 4 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL, PLACEBO-CONTROLLED INDUCTION STUDY OF MIRIKIZUMAB IN CONVENTIONAL-FAILED AND BIOLOGIC-FAILED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 1) | Eli Lilly and Company | $2,073 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE- CONTROLLED, TREAT-THROUGH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE | Eli Lilly and Company | $1,099 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED MAINTENANCE STUDY OF MIRIKIZUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (LUCENT 2) | Eli Lilly and Company | $981.75 | 1 |
| A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE | Eli Lilly and Company | $80.86 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 336 | 531 | $178,623 | $27,462 |
| 2022 | 12 | 377 | 5,066 | $361,666 | $108,446 |
| 2021 | 20 | 735 | 23,669 | $1.6M | $658,888 |
| 2020 | 25 | 782 | 13,355 | $1.3M | $552,607 |
Total Patients
2,230
Total Services
42,621
Medicare Billing
$1.3M
Procedure Codes
65
All Medicare Procedures & Services
65 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 46 | 46 | $50,784 | $8,961 | 17.6% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2023 | 72 | 215 | $30,960 | $5,522 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 28 | 43 | $19,823 | $3,578 | 18.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 34 | 36 | $21,564 | $2,748 | 12.7% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 41 | 41 | $35,629 | $2,372 | 6.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $10,101 | $2,076 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 25 | 28 | $9,156 | $1,612 | 17.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 69 | 101 | $606.00 | $593.88 | 98.0% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2022 | 12 | 4,500 | $171,000 | $78,154 | 45.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 37 | 37 | $38,295 | $7,216 | 18.8% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2022 | 69 | 211 | $28,696 | $5,008 | 17.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 34 | 47 | $21,197 | $4,368 | 20.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 45 | 45 | $39,156 | $3,199 | 8.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 38 | 40 | $22,520 | $2,549 | 11.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 23 | 23 | $10,764 | $2,387 | 22.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 31 | 31 | $9,858 | $1,915 | 19.4% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 17 | 17 | $11,492 | $1,759 | 15.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 16 | $4,720 | $873.95 | 18.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 14 | $3,458 | $766.90 | 22.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 47 | 85 | $510.00 | $251.46 | 49.3% |
| J3380 | Injection, vedolizumab, 1 mg | Office | 2021 | 31 | 18,900 | $604,800 | $315,202 | 52.1% |
| J3357 | Ustekinumab, for subcutaneous injection, 1 mg | Office | 2021 | 11 | 1,530 | $466,650 | $212,792 | 45.6% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2021 | 22 | 2,190 | $219,000 | $73,227 | 33.4% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 84 | 84 | $90,632 | $16,233 | 17.9% |
| 88305 | Pathology examination of tissue using a microscope, intermediate complexity | Office | 2021 | 135 | 366 | $49,044 | $8,679 | 17.7% |
About Dr. Daniel Van Handel, M.D
Dr. Daniel Van Handel, M.D is a Gastroenterology healthcare provider based in Plymouth, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2007. The National Provider Identifier (NPI) number assigned to this provider is 1093832453.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Van Handel, M.D has received a total of $69,506 in payments from pharmaceutical and medical device companies, with $1,716 received in 2024. These payments were reported across 54 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($50,625).
As a Medicare-enrolled provider, Van Handel has provided services to 2,230 Medicare beneficiaries, totaling 42,621 services with total Medicare billing of $1.3M. Data is available for 4 years (2020–2023), covering 65 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Plymouth, MN
- Active Since 03/23/2007
- Last Updated 12/09/2015
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1093832453
Products in Payments
- REBYOTA (Biological) $37,908
- ENTYVIO (Biological) $7,831
- Entyvio (Biological) $5,786
- CONMED BIOPSY (Device) $1,440
- General - Therapies (Device) $125.88
- EXALT Model D (Device) $123.63
- IBSRELA (Drug) $66.35
- LINX Reflux Management System (Device) $65.90
- XELJANZ (Drug) $37.27
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Plymouth
Brian Gill, M.d, M.D
Gastroenterology — Payments: $7,209
Gastroenterology $7,209
Jose Vega Peralta, M.d, M.D
Gastroenterology — Payments: $6,849
Gastroenterology $6,849
Mitchell Oliver, M.d, M.D
Gastroenterology — Payments: $2,306
Gastroenterology $2,306
Soroya Rahaman, Md, MD
Gastroenterology — Payments: $2,225
Gastroenterology $2,225
Maysaa El Zoghbi, M.d, M.D
Gastroenterology — Payments: $1,149
Gastroenterology $1,149
Jonathan Russo, Md, MD
Gastroenterology — Payments: $711.21
Gastroenterology $711.21